LIMMATECH BIOLOGICS AG

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

October 09, 2023 04:00 AM Eastern Daylight Time SCHLIEREN, Switzerland – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against … Continue reading LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Angel Reyes

Angel Reyes Joins Altasciences as General Manager of CDMO Services

October 06, 2023 10:00 AM Eastern Daylight Time LAVAL, Québec – Altasciences is pleased to welcome Angel Reyes as General Manager, Contract Development and Manufacturing Organization (CDMO) Services.“Angel’s scientific knowledge and wealth of experience gained over years in managing manufacturing operations, combined with his ability to find innovative solutions and improve day-to-day operations, makes him a valuable addition to the CDMO team. I am confident he … Continue reading Angel Reyes Joins Altasciences as General Manager of CDMO Services

Odyssey Therapeutics

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

October 04, 2023 08:00 AM Eastern Daylight Time BOSTON – Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer. In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets. Additionally, he will be responsible for selecting, prioritizing and accelerating … Continue reading Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

SONOMA BIOTHERAPEUTICS

Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

Co-founder Fred Ramsdell, Ph.D., to retire from Chief Scientific Officer position September 29, 2023 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif. & SEATTLE – Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, … Continue reading Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer

Ligand

Ligand Appoints Martine Zimmermann to its Board of Directors

September 26, 2023 05:05 PM Eastern Daylight Time SAN DIEGO – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board. “We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and … Continue reading Ligand Appoints Martine Zimmermann to its Board of Directors